Higher dose of breast cancer drug faslodex tested in new trial

NCT ID NCT00585507

Ongoing Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a higher dose (500 mg) of the hormone therapy fulvestrant (Faslodex) as a first treatment for postmenopausal women with hormone receptor positive metastatic breast cancer. The study aims to see if this higher dose improves clinical benefit rates compared to the standard dose. Forty women will receive injections on days 1, 15, and 29, then monthly, with researchers tracking tumor response, side effects, and how long the benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fulvestrant (Faslodex)
What this could lead to: If successful, this higher dose of fulvestrant could improve control of metastatic breast cancer, delaying disease progression and extending the time patients feel well.
What could go wrong: This is a small phase 2 trial with only 40 participants, so results may not apply broadly. The higher dose could also cause more side effects, and the drug may not work better than the standard dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Lowell General Hospital

Lowell, Massachusetts, 01854, United States
Massachusetts General Hosptial

Boston, Massachusetts, 02114, United States
South Shore Hospital

South Weymouth, Massachusetts, 02190, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.